The Effect of Bright Light Treatment on Rest-Activity Rhythms in People with Dementia: A 24-Week Cluster Randomized Controlled Trial

被引:5
|
作者
Kolberg, Eirin [1 ]
Pallesen, Stale [2 ,3 ,4 ]
Hjetland, Gunnhild Johnsen [1 ,5 ]
Nordhus, Inger Hilde [1 ,6 ]
Flo-Groeneboom, Elisabeth [1 ]
机构
[1] Univ Bergen UiB, Fac Psychol, Dept Clin Psychol, N-5009 Bergen, Norway
[2] Univ Bergen UiB, Fac Psychol, Dept Psychosocial Sci, N-5015 Bergen, Norway
[3] Haukeland Hosp, Norwegian Competence Ctr Sleep Disorders, N-5021 Bergen, Norway
[4] North West Univ, Optentia, Vaal Triangle Campus, ZA-1911 Vanderbijlpark, South Africa
[5] City Dept Hlth & Care, N-5007 Bergen, Norway
[6] Univ Oslo UiO, Fac Med, Dept Behav Med, N-0372 Oslo, Norway
来源
CLOCKS & SLEEP | 2021年 / 3卷 / 03期
关键词
dementia; nursing homes; bright light therapy; rest-activity rhythms; actigraphy; circadian rhythms; clinical trial; CIRCADIAN ACTIVITY RHYTHMS; NURSING-HOME RESIDENTS; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; INSTITUTIONALIZED PATIENTS; MELATONIN SECRETION; SLEEP; EXPOSURE; DISTURBANCES; INTERVENTION;
D O I
10.3390/clockssleep3030032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Bright light treatment is an effective way to influence circadian rhythms in healthy adults, but previous research with dementia patients has yielded mixed results. The present study presents a primary outcome of the DEM.LIGHT trial, a 24-week randomized controlled trial conducted at nursing homes in Bergen, Norway, investigating the effects of a bright light intervention. The intervention consisted of ceiling-mounted LED panels providing varying illuminance and correlated color temperature throughout the day, with a peak of 1000 lx, 6000 K between 10 a.m. and 3 p.m. Activity was recorded using actigraphs at baseline and after 8, 16, and 24 weeks. Non-parametric indicators and extended cosine models were used to investigate rest-activity rhythms, and outcomes were analyzed with multi-level regression models. Sixty-one patients with severe dementia (median MMSE = 4) were included. After 16 weeks, the acrophase was advanced from baseline in the intervention group compared to the control group (B = -1.02, 95%; CI = -2.00, -0.05). There was no significant difference between the groups on any other rest-activity measures. When comparing parametric and non-parametric indicators of rest-activity rhythms, 25 out of 35 comparisons were significantly correlated. The present results indicate that ambient bright light treatment did not improve rest-activity rhythms for people with dementia.
引用
收藏
页码:449 / 464
页数:16
相关论文
共 50 条
  • [31] Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761 (R) treatment: additional results from a 24-week randomized, placebo-controlled trial
    Nacu, Anatol
    Hoerr, Robert
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2016, 8 : 1 - 6
  • [32] LIMITED BENEFIT OF TREATMENT OF DIABETIC POLYNEUROPATHY WITH AN ALDOSE REDUCTASE INHIBITOR - A 24-WEEK CONTROLLED TRIAL
    FAGIUS, J
    BRATTBERG, A
    JAMESON, S
    BERNE, C
    DIABETOLOGIA, 1985, 28 (06) : 323 - 329
  • [33] Efficacy and tolerability of galantamine and galantamine combined with nimodipine in mixed dementia: A 24-week, randomized, placebo-controlled exploratory trial (The REMIX study)
    Bottino, Cassio
    Caramelli, P.
    Laks, J.
    Palmini, A.
    Nitrini, R.
    Chaves, M.
    Forlenza, O.
    Vale, F.
    Barbosa, M.
    Machado, J.
    Charchat-Fichman, H.
    Lawson, F.
    INTERNATIONAL PSYCHOGERIATRICS, 2011, 23 : S255 - S256
  • [34] Effect of a 24-Week Concurrent Exercise Intervention on Neck Adiposity and Its Distribution in Young Adults: The ACTIBATE Randomized Controlled Trial
    Arias-Tellez, Maria Jose
    Acosta, Francisco M.
    Merchan-Ramirez, Elisa
    Martinez-Tellez, Borja
    Delgado, Guillermo-Sanchez
    Llamas-Elvira, Jose M.
    Ruiz, Jonatan R.
    INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM, 2023, 33 (05) : 255 - 264
  • [35] A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders
    McElroy, Susan L.
    Frye, Mark A.
    Altshuler, Lori L.
    Suppes, Trisha
    Hellemann, Gerhard
    Black, David
    Mintz, Jim
    Kupka, Ralph
    Nolen, Willem
    Leverich, Gabriele S.
    Denicoff, Kirk D.
    Post, Robert M.
    Keck, Paul E., Jr.
    BIPOLAR DISORDERS, 2007, 9 (04) : 426 - 434
  • [36] Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
    Holdstock, Louis
    Cizman, Borut
    Meadowcroft, Amy M.
    Biswas, Nandita
    Johnson, Brendan M.
    Jones, Delyth
    Kim, Sung Gyun
    Zeig, Steven
    Lepore, John J.
    Cobitz, Alexander R.
    CLINICAL KIDNEY JOURNAL, 2019, 12 (01) : 129 - 138
  • [37] Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial
    Usall, Judith
    Huerta-Ramos, Elena
    Labad, Javier
    Cobo, Jesus
    Nunez, Christian
    Creus, Marta
    Garcia Pares, Gemma
    Cuadras, Daniel
    Franco, Jose
    Miquel, Eva
    Cesar Reyes, Julio
    Roca, Mercedes
    SCHIZOPHRENIA BULLETIN, 2016, 42 (02) : 309 - 317
  • [38] Neurorehabilitation Therapy in Spinocerebellar Ataxia Type 2: A 24-Week, Rater-Blinded, Randomized, Controlled Trial
    Cesar Rodriguez-Diaz, Julio
    Velazquez-Perez, Luis
    Rodriguez Labrada, Roberto
    Aguilera Rodriguez, Raul
    Laffita Perez, Dalina
    Canales Ochoa, Nalia
    Medrano Montero, Jacqueline
    Estupinan Rodriguez, Annelie
    Osorio Borjas, Marcos
    Gongora Marrero, Mariela
    Reynaldo Cejas, Lorenzo
    Gonzalez Zaldivar, Yanetza
    Almaguer Gotay, Dennis
    MOVEMENT DISORDERS, 2018, 33 (09) : 1481 - 1487
  • [39] Weight Loss with a Behavioral Program Using Meal Replacements, Fruit and Vegetables: A 24-Week Randomized, Controlled Trial
    Anderson, James W.
    Reynolds, Raymond
    Rinsky, Jessica
    Bush, Heather
    Washnock, Carla
    OBESITY, 2009, 17 : S265 - S265
  • [40] Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial
    Insull, W
    Toth, P
    Mullican, W
    Hunninghake, D
    Burke, S
    Donovan, JM
    Davidson, MH
    MAYO CLINIC PROCEEDINGS, 2001, 76 (10) : 971 - 982